What clinical results has EMSELLA shown for men?

Published clinical research in men has reported improvements in urinary incontinence, pad dependence, nocturia, quality of life and, in smaller early studies, aspects of erectile and sexual function following high-intensity focused electromagnetic pelvic floor treatment.

A continence questionnaire measures a different outcome from an erection or sexual-function questionnaire. Keep each result attached to its own study population, sample size, protocol and follow-up; improvement in one outcome should not be reported as improvement in the other.

Can EMSELLA Help With Sexual Function or Erection Quality in Men? · EMSELLA after prostate surgery: what the male incontinence pilot study found · Measuring pelvic-floor progress: what is useful to track?

The strongest direct EMSELLA evidence in men currently relates to urinary incontinence after prostate surgery.

Published studies have reported outcomes including:

The evidence is encouraging, but the male EMSELLA literature remains smaller than the female urinary-incontinence evidence base.

At ¹EM, we use these results to inform treatment discussions, not to promise that every patient will achieve the same percentages.

These figures come from different studies involving different men, treatment schedules and outcome measures. They should not be combined into an expected result for one individual patient.

A 2025 clinical study evaluated 27 men with persistent urinary incontinence following radical prostatectomy.

The men underwent:

Their average urinary incontinence score, measured using the ICIQ-SF, decreased from 10.58 before treatment to 5.43 after the sixth session.

At one-month follow-up, the score had fallen further to 4.16.

That represented average improvements of:

53.1% after treatment

and

60.6% at one month

compared with baseline.

Pad dependence also decreased substantially in that 2025 study.

Among participants using pads at baseline, average use decreased from 2.57 pads per day to:

1.45 pads per day after the six-session course

and

1.13 pads per day at one-month follow-up.

That represented average reductions of approximately:

42.7% after treatment

and

53.7% at one month.

Some men stopped using pads altogether.

After six sessions, 9 of the 27 men reported no longer requiring pads.

At one month, this had increased to 13 of 27 men.

These are particularly useful clinical outcomes because they represent something patients experience in everyday life rather than simply a change in a questionnaire score.

Yes, in that study.

Both urinary symptom scores and pad use improved further between the end of the six-session treatment course and the one-month follow-up.

This is consistent with the idea that pelvic floor muscle adaptation can continue after the final treatment session.

It is one reason ¹EM does not consider the result on the day of session six to necessarily be the final result.

A 2024 pilot study by Javier Azparren and Judson Brandeis evaluated 10 men with persistent urinary incontinence following prostatectomy.

The men received:

This is particularly relevant to the standard initial EMSELLA schedule used at ¹EM.

Every participant showed improvement in the study's quality-of-life assessment.

Before treatment, all 10 men were using absorbent pads, averaging approximately 2.5 pads per day.

Following treatment:

The study also reported a 30.4% improvement in the measured impact of urinary incontinence.

Again, this was a very small pilot study, so these percentages should be interpreted as encouraging early findings rather than expected individual results.

Urinary leakage can affect considerably more than bathroom use.

The Azparren study used the King's Health Questionnaire to examine how incontinence affected men's everyday lives.

The role limitations domain, which measures limitations placed on normal daily activities, improved by approximately 31.4% following treatment.

That matters because successful continence treatment is not simply about achieving a better questionnaire score.

Patients often want to:

The largest improvement in the Azparren pilot was observed in the sleep/energy domain.

The score improved by approximately 53.3%.

This should not be interpreted as EMSELLA being a treatment for insomnia or fatigue.

Rather, urinary incontinence and nocturnal urinary problems can disrupt sleep and quality of life.

Improving the urinary problem may therefore reduce some of that secondary burden.

The same pilot study reported approximately 42.5% improvement in the emotional domain of the King's Health Questionnaire.

Urinary incontinence can affect:

Improving continence can therefore have consequences beyond the bladder itself.

EMSELLA should not, however, be marketed as a treatment for depression or another mental-health disorder.

The published result refers specifically to the emotional burden associated with urinary incontinence in this small group of men.

The social limitations domain improved by approximately 42.2% in the same 10-man pilot study.

Again, the correct interpretation is:

reducing urinary symptoms may reduce the degree to which incontinence interferes with social life.

It is not a promise that EMSELLA directly produces confidence or psychological wellbeing.

Yes, in early male HIFEM research.

A 2024 study led by Judson Brandeis evaluated men with urinary symptoms accompanied by erectile dysfunction.

Twenty men had complete data available for analysis following HIFEM pelvic floor treatment.

Their urinary symptoms improved from a moderate average level to a mild average level.

Among individual symptoms, researchers reported approximately:

following treatment.

No.

Nocturia means waking during the night to urinate.

It can have many possible contributors, including:

Pelvic floor dysfunction may be part of the picture in some men, but it should not be assumed to explain every case.

At ¹EM, significant nocturia or urinary frequency is assessed clinically rather than automatically treated as weak pelvic floor muscles.

Early research has reported improvements in selected measures of male sexual function.

In the 2024 Brandeis study, men reported a 37% improvement in their ability to maintain an erection through completion of intercourse following HIFEM pelvic floor treatment.

Other reported changes included:

These findings are interesting, but the study was small and observational.

They should therefore be considered early evidence, rather than proof that every man with erectile dysfunction will respond to EMSELLA.

Certain male pelvic floor muscles contribute to erection rigidity and maintenance.

Pelvic floor muscle rehabilitation has separately been studied as a treatment strategy for erectile dysfunction.

EMSELLA provides intensive electromagnetic stimulation of these muscles without requiring the patient to voluntarily produce every contraction.

The biological rationale is therefore credible.

However, erectile dysfunction can also arise from:

At ¹EM, Dr Emir assesses whether pelvic floor dysfunction appears relevant rather than assuming all erectile dysfunction has the same cause.

Related article: Can EMSELLA Help With Sexual Function or Erection Quality?

The evidence is broader than the small EMSELLA studies alone.

A 2026 rapid evidence assessment examined extracorporeal magnetic stimulation for urinary incontinence in adult men.

Researchers identified:

Most participants were men experiencing urinary incontinence following prostatectomy.

The review found that magnetic stimulation:

However, the authors concluded that the evidence remains limited and that larger, better-quality trials are needed.

This review included electromagnetic stimulation technologies more broadly and was not limited specifically to the EMSELLA device.

Yes, for extracorporeal magnetic pelvic floor stimulation in men.

A 2025 quadruple-blind randomised trial involved 40 men with urinary incontinence following radical prostatectomy.

Twenty received active magnetic stimulation and twenty received sham treatment.

After eight weeks, researchers reported:

No serious treatment-related side effects were reported.

This trial used a different magnetic-stimulation chair rather than EMSELLA, so it should not be presented as direct EMSELLA evidence.

It does, however, strengthen the broader evidence that extracorporeal magnetic pelvic floor stimulation can produce clinically meaningful effects in men following prostate surgery.

At present, the clearest male clinical case is post-prostatectomy urinary incontinence.

The evidence includes:

The evidence for sexual and erectile function is promising but less mature.

That distinction is important.

At ¹EM, we can be confident discussing EMSELLA as a pelvic floor rehabilitation option for appropriately selected men with urinary continence problems, particularly after prostate treatment.

For erectile dysfunction, we explain that pelvic floor strengthening may form one part of the treatment strategy where pelvic floor function is contributing.

No.

The published percentages describe groups of participants in clinical studies.

Individual response can depend on factors including:

A result such as 53% average improvement does not mean every patient improves by exactly 53%.

Some patients improve more.

Some improve less.

Some may not achieve a clinically meaningful response.

Several direct EMSELLA male studies measured meaningful changes after completing the treatment program.

In the 2025 post-prostatectomy study, improvement was documented after six sessions and increased further at the one-month review.

This is consistent with pelvic floor strengthening being a progressive process rather than an instant treatment effect.

Related article: How Soon Will I Notice Results?

Different studies have used different protocols.

The 2025 post-prostatectomy EMSELLA study used:

6 sessions

2 sessions per week

28 minutes per session.

The Azparren post-prostatectomy pilot used the same basic six-session, twice-weekly schedule.

The Brandeis study examining combined urinary and sexual outcomes used a longer protocol of 10 weekly sessions.

At ¹EM, the standard initial EMSELLA program is generally six sessions twice weekly, with the clinical plan based on the individual presentation rather than copying every research protocol.

Related article: How Many EMSELLA Sessions Are Recommended?

We focus on the problem that brought you to treatment.

For urinary incontinence, relevant changes can include:

For men with combined sexual-health concerns, relevant discussion may include:

The goal is not simply to complete a treatment package.

It is to determine whether the symptoms affecting your life are improving.

This evidence may be particularly relevant if you are a man experiencing:

You do not need to determine yourself whether the pelvic floor is responsible.

That is part of the clinical assessment.

You can still discuss pelvic floor function with Dr Emir.

Pelvic floor muscles contribute to erectile mechanics, and early HIFEM research is encouraging.

However, the evidence base is currently stronger for urinary continence than for ED.

Erectile dysfunction can also be an indicator of broader vascular or medical issues.

It therefore deserves appropriate assessment rather than immediately being treated as isolated pelvic floor weakness.

No.

Men following prostate surgery should continue appropriate specialist and cancer follow-up.

EMSELLA is a pelvic floor rehabilitation treatment.

It does not replace:

At ¹EM, EMSELLA is used within a clinical pathway rather than as a substitute for necessary medical care.

The male evidence is encouraging, but patients deserve to understand its limitations.

Several EMSELLA studies have:

The 2024 Azparren study included only 10 men.

The 2024 Brandeis analysis included complete data from 20 men and was not sham controlled.

The newer 2025 direct EMSELLA® study included 27 men.

The broader 2026 evidence review concluded that results were generally positive but that the field still needs larger, high-quality controlled trials.

This means we can reasonably describe the evidence as promising and increasingly supportive, particularly for male urinary incontinence.

It would be premature to claim guaranteed results.

Yes.

Published studies have evaluated HIFEM and EMSELLA® in men with urinary incontinence, particularly following radical prostatectomy, as well as men experiencing combined urinary and sexual-function concerns.

A 2025 EMSELLA study reported an average 53.1% improvement in urinary incontinence scores after six sessions, increasing to 60.6% at one month.

Clinical studies have reported significant reductions in pad dependence.

In the 2025 EMSELLA study, average pad use fell approximately 42.7% after treatment and 53.7% at one month.

Yes, in published studies.

In the 2025 study, 9 of 27 men reported no longer requiring pads after treatment, increasing to 13 of 27 at one month.

Early male HIFEM research reported improvement in nocturia.

However, nocturia can have several different causes and should be medically assessed rather than automatically attributed to pelvic floor weakness.

Early research has reported improvements in erection maintenance and other sexual-function measures.

The evidence remains less developed than the evidence for urinary incontinence.

A small 2024 post-prostatectomy pilot reported improvements in sleep/energy, emotions, social limitations and daily role limitations as urinary symptoms improved.

These are quality-of-life outcomes associated with reduced incontinence burden rather than direct treatment of sleep or emotional disorders.

Yes, broader extracorporeal magnetic pelvic floor stimulation has been tested against sham treatment in men after prostatectomy and has demonstrated superior continence and quality-of-life outcomes.

That trial did not specifically use the EMSELLA device.

No.

Clinical study results describe averages and outcomes across groups of patients. Individual treatment response varies.

At ¹EM, the standard initial course is generally six sessions, usually twice weekly over approximately three weeks.

No.

Men can experience pelvic floor problems for other reasons.

However, the strongest direct male clinical evidence currently relates to post-prostatectomy urinary incontinence.

The clinical picture has moved beyond simply saying:

"Men have pelvic floor muscles too."

We now have published male data showing measurable changes in:

The strongest evidence is currently for urinary incontinence and post-prostate rehabilitation.

Sexual-function findings are promising and continue to be investigated.

For ¹EM, that means the treatment decision can be based on a growing clinical evidence base while still being personalised to the individual man.

Clinical-study percentages are useful.

What matters more is whether pelvic floor strengthening makes sense for your symptoms, medical history and goals.

At ¹EM, Dr Emir can confidentially assess urinary leakage, previous prostate treatment, pelvic floor function and associated sexual-health concerns and determine whether EMSELLA® is appropriate.

CTA heading: See Whether EMSELLA® Could Help Your Pelvic Health

CTA description: Book a confidential complimentary men's health consultation to review your symptoms, understand the evidence and determine whether EMSELLA® should form part of your personalised plan.

CTA button: Book a Men's Health Consultation

Internal links:

Men's Health at ¹EM:https://menshealth.1em.com.au/

EMSELLA® at ¹EM:https://emsella.1em.com.au/

Related article: Does EMSELLA® Help Men as Well?

Related article: Can EMSELLA® Help With Sexual Function or Erection Quality?

Related article: How Soon Will I Notice Results?

Related article: How Many EMSELLA® Sessions Are Recommended?

Related article: Is EMSELLA® Safe?

1. Tosun H, Akinsal EC, Bas U, et al. Evaluating the Efficacy of High-Intensity Focused Electromagnetic Therapy for Postprostatectomy Incontinence in Men. Therapeutics and Clinical Risk Management. 2025. PMID: 40909763.

Twenty-seven men with persistent urinary incontinence following radical prostatectomy underwent six EMSELLA® sessions twice weekly. Mean ICIQ-SF scores improved by 53.1% after treatment and 60.6% at one month, with substantial reductions in daily pad use. No adverse events were reported.

2. Azparren J, Brandeis J. HIFEM Procedure Enhances the Quality of Life in Elderly Men with Post-Prostatectomy Incontinence: A Pilot Study. Medical & Surgical Urology. 2024;13:340.

Ten men with persistent post-prostatectomy incontinence received six HIFEM sessions. Significant improvements were reported in urinary incontinence impact, pad use, sleep/energy, emotional burden, social limitations and daily role limitations.

3. Brandeis J. Improving Male Pelvic Health: Efficacy of HIFEM Muscle Stimulation for Urinary Function and Sexual Dysfunction in Men. Reproductive System & Sexual Disorders. 2024.

Twenty men with complete outcome data were analysed following HIFEM treatment. Improvements were reported in nocturia, urinary frequency, erection maintenance, intercourse satisfaction, ejaculation and orgasm-related measures.

4. Brandeis J. Application of HIFEM Therapy Improves Orgasmic, Urinary and Erectile Function by Stimulation of Pelvic Floor Muscles. The Journal of Sexual Medicine. 2024;21(Supplement 1).

A separate published conference abstract involving 28 men reported significant improvements in urinary and sexual-function measures after HIFEM pelvic floor stimulation. The disclosure states that the study received industry funding.

5. Wong R, Welk B. A Rapid Evidence Assessment for Extracorporeal Magnetic Stimulation to Treat Urinary Incontinence in Men. Canadian Urological Association Journal. 2026;20(2):63-70. PMID: 41191830.

Nine studies involving 181 men treated with extracorporeal magnetic stimulation were identified. Evidence was limited but generally positive, with several studies showing earlier continence recovery, reduced pad use and improved quality of life.

6. Unal B, Sarsan A, Yildiz N, Alkan H. Efficacy of Magnetic Stimulation in Men With Urinary Incontinence After Radical Prostatectomy: A Randomized, Quadruple-Blind, Sham-Controlled Clinical Trial. Neurourology and Urodynamics. 2025;44:1140-1148.

Forty men were randomised to active or sham extracorporeal magnetic stimulation. Active treatment produced significantly greater improvement and continence rates and improved multiple urinary and quality-of-life outcomes. This study evaluated magnetic stimulation using a device other than EMSELLA® and therefore supports the broader treatment mechanism rather than serving as direct EMSELLA® evidence.

This article provides general information about published clinical research and does not predict an individual treatment result. Study populations, protocols and outcomes differ, and several male EMSELLA® studies remain small. Individual suitability and expected benefit depend on symptoms, medical history, previous prostate treatment, pelvic floor function and other clinical factors.